Anabolic deficiency in men with chronic heart failure: Prevalence and detrimental impact on survival

Ewa A. Jankowska, Bartosz Biel, Jacek Majda, Alicja Szklarska, Monika Lopuszanska, Marek Medras, Stefan D. Anker, Waldemar Banasiak, Philip A. Poole-Wilson, Piotr Ponikowski

Research output: Contribution to journalArticlepeer-review


BACKGROUND - The age-related decline of circulating anabolic hormones in men is associated with increased morbidity and mortality. We studied the prevalence and prognostic consequences of deficiencies in circulating total testosterone (TT) and free testosterone, dehydroepiandrosterone sulfate (DHEAS), and insulin-like growth factor-1 (IGF-1) in men with chronic heart failure (CHF). METHODS AND RESULTS - Serum levels of TT, DHEAS, and IGF-1 were measured with immunoassays in 208 men with CHF (median age 63 years; median left ventricular ejection fraction 33%; New York Heart Association class I/II/III/IV, 19/102/70/17) and in 366 healthy men. Serum levels of free testosterone were estimated (eFT) from levels of TT and sex hormone binding globulin. Deficiencies in DHEAS, TT, eFT, and IGF-1, defined as serum levels at or below the 10th percentile of healthy peers, were seen across all age categories in men with CHF. DHEAS, TT, and eFT were inversely related to New York Heart Association class irrespective of cause (all P1 anabolic hormone identifies groups with a higher mortality.

Original languageEnglish
Pages (from-to)1829-1837
Number of pages9
Issue number17
Publication statusPublished - Oct 2006


  • Anabolic hormones
  • Heart failure
  • Prognosis

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Anabolic deficiency in men with chronic heart failure: Prevalence and detrimental impact on survival'. Together they form a unique fingerprint.

Cite this